Vaccine composition for preventing infection with chicken infectious anemia virus
The attenuated SHK17 strain of CIAV, with its reduced pathogenicity and enhanced antibody titer, addresses the ineffectiveness of existing vaccines by providing a more robust and sustained immune response against chicken infectious anemia, effectively reducing disease severity and mortality in poultry.
Patent Information
- Application Number
- PCT/KR2024/006589
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-14
- Publication Date
- 2024-11-21
AI Technical Summary
Current vaccines for chicken infectious anemia virus (CIAV) are not always effective in preventing the disease, as they may not induce a sufficient protective immune response or maintain antibody titers for a long duration, leading to high mortality rates and secondary infections in young chicks.
Development of an attenuated strain of CIAV, designated SHK17 (accession number: KCTC14732BP), which is significantly less pathogenic than the parent virus and has a higher antibody titer with a longer maintenance period, used in a vaccine composition to provide effective immunity against CIAV.
The attenuated SHK17 strain demonstrates superior efficacy compared to commercial vaccines by inducing a strong and long-lasting immune response, significantly reducing the severity of CIAV infection and mortality rates in poultry.
Smart Images

Figure KR2024006589_21112024_PF_FP_ABST
Abstract
Description
Vaccine composition for preventing infection with chicken infectious anemia virus
[0001] The present invention relates to a vaccine composition for preventing infection with chicken infectious anemia.
[0002]
[0003] Vaccines are used to prevent infectious diseases and treat existing ones. Infectious diseases are caused by infectious agents, including viruses, bacteria, parasites, and other fungi. Many reagents and methods have been developed to prevent and treat infectious diseases in all species, including mammals, birds, fish, and primates.
[0004] Vaccination programs are particularly important for commercially raised animals in the food industry. Birds are a primary target for many forms of infectious disease. Farmers and commercial chickens, turkeys, and other poultry are routinely vaccinated to protect them from environmental exposure to pathogens.
[0005] Chicken infectious anemia (CIA), a representative immunosuppressive disease in chickens, is caused by the CIA virus. When young chicks at 1-2 weeks of age are exposed to the virus, their immune functions are weakened, including aplastic anemia, severe thymic atrophy, and leukopenia due to damage to red blood cells and lymphocytes. This causes them to be easily exposed to respiratory viruses, bacteria, and fungi, which induces secondary complex infections. In particular, when young chicks are infected with this virus, their growth is slowed, and the mortality rate is usually 10-20%, but in severe flocks, the mortality rate can reach up to 60%. Since the disease is transmitted through the egg line, it is possible to protect future chicks by vaccinating breeding hens from infection with field viruses when they are 6 weeks of age or older.
[0006] Hatched birds are briefly exposed to pathogenic microorganisms after birth. Although initially protected from pathogens by antibodies inherited from their mothers, this protection is only temporary, and the birds' immature immune systems begin to protect them from pathogens. It is generally advisable to prevent infection in young birds, which are most susceptible. Furthermore, it is advisable to prevent infection in older birds, as diseases can spread rapidly, especially when confined to confined spaces.
[0007] In most commercial poultry, newly hatched chicks are given specific parenteral vaccines at hatching. Because exposure to pathogens occurs at a very early age, chicks must be vaccinated before being placed in a coop or incubator. Vaccination regimens must be individualized for each bird and carry the risk of accidental autoinoculation. However, these vaccinations are not always effective. If antibodies fail to develop after vaccination, resulting in a sufficient protective immune system, they cannot effectively prevent disease.
[0008] Therefore, there is a need to develop a new vaccine that can effectively prevent infection with the chicken infectious anemia virus by demonstrating high antibody titers and long-term retention.
[0009]
[0010] The present inventors isolated a novel chicken infectious anemia virus, subcultured it a specific number of times to obtain an isolate, and confirmed its preventive effect against chicken infectious anemia virus, thereby completing the present invention.
[0011] Therefore, the purpose of the present invention is to provide an attenuated strain of chicken infectious anemia virus.
[0012] Another object of the present invention is to provide a vaccine composition for preventing chicken infectious anemia.
[0013] Another object of the present invention is to provide a method for preventing infection with the chicken infectious anemia virus.
[0014]
[0015] To achieve the above purpose, the present invention provides an attenuated strain SHK17 of chicken infectious anemia virus (Accession No.: KCTC14732BP).
[0016] In addition, in order to achieve the other purpose mentioned above, the present invention provides a vaccine composition for preventing chicken infectious anemia, which includes an attenuated strain of chicken infectious anemia virus, SHK17 (Accession No.: KCTC14732BP).
[0017] In addition, in order to achieve the above another object, the present invention provides a method for preventing infection with avian infectious anemia virus, comprising the step of administering a vaccine composition according to the present invention to poultry.
[0018]
[0019] The attenuated strain of chicken infectious anemia virus according to the present invention, obtained through serial passage of the parent virus, has significantly lower pathogenicity than the parent virus or the virus obtained by serial passage of the parent virus 45 times, and exhibits a higher antibody titer and a longer retention period than the commercially available vaccine, and thus can be usefully utilized as a vaccine composition for preventing CIAV.
[0020]
[0021] Figure 1 shows the results of phylogenetic analysis based on the base sequence of the whole genome of 28 strains of chicken infectious anemia virus isolated in Korea, and the genotypes were divided into types I, IIa, IIb, IIIa, and IIIb. In Figure 1, types IIa (2 strains), IIb (9 strains), IIIa (8 strains), and IIIb (9 strains) are indicated by red boxes, and commercially available vaccines are indicated by blue shapes.
[0022] Figure 2 shows the results of a comparison of the major amino acid sequences of the VP1 protein in 28 strains of chicken infectious anemia viruses isolated in Korea. In Figure 2, the red box indicates the amino acid sequence of the parent virus identified in the present invention.
[0023] Figure 3 shows the results of investigating the possibility of the attenuated SHK17 strain deposited with the accession number KCTC14732BP according to the present invention as a live vaccine, comparing the macroscopic lesion findings of the thymus and bone marrow by treatment group at 14 days after inoculation with CIAV including the attenuated SHK17 strain according to the present invention and a commercial vaccine. Figure 3A is the group inoculated with the attenuated SHK17 strain according to the present invention, Figure 3B is the group inoculated with the commercial vaccine P4, Figure 3C is the experimental group inoculated with a low titer of 17A008-P45 obtained by passage 45 times of the isolated chicken infectious anemia parent virus, Figure 3D is the experimental group inoculated with the 17AD008 at a high titer, and Figure 3E is the negative control group.
[0024] Figure 4 shows the results of investigating the possibility of the SHK17 attenuated strain deposited with the accession number KCTC14732BP according to the present invention as a live vaccine, and confirming the packed cell volume (PCV) and ELISA antibody titer of each experimental group. FIG. 4A is a group vaccinated with the attenuated SHK17 strain according to the present invention, FIG. 4B is a group vaccinated with the commercial vaccine P4, FIG. 4C is an experimental group vaccinated with a low titer of 17A008-P45 obtained by passage 45 times of the isolated chicken infectious anemia maternal virus, FIG. 4D is an experimental group vaccinated with a low titer of the isolated chicken infectious anemia maternal virus, FIG. 4E is an experimental group vaccinated with a high titer of the above 17A008-P45, FIG. 4F is an experimental group vaccinated with a high titer of the above 17AD008, and FIG. 4G is a negative control group.
[0025] Figure 5 shows the results of comparing the protective ability of the SHK17 attenuated strain deposited with the accession number KCTC14732BP according to the present invention and the commercial vaccine against challenge with chicken infectious anemia virus. Figure 5A shows the experimental group that was inoculated with the SHK17 attenuated strain deposited with the accession number KCTC14732BP according to the present invention and then challenged with 17AD008 CIAV, Figure 5B shows the experimental group that was inoculated with the commercial vaccine and then challenged with 17AD008 CIAV, Figure 5C shows the positive control group that was not vaccinated but was vaccinated with 17AD008 CIAV, and Figure 5D shows the negative control group.
[0026] Figure 6 shows the results of comparing the antibody formation ability of the attenuated SHK17 strain deposited with the accession number KCTC14732BP according to the present invention and the commercial vaccine to challenge with the chicken infectious anemia virus. Figure 6A is an experimental group that was inoculated with the attenuated SHK17 strain deposited with the accession number KCTC14732BP according to the present invention and then challenged with 17AD008 CIAV, Figure 6B is an experimental group that was inoculated with the commercial vaccine and then challenged with 17AD008 CIAV, Figure 6C is a positive control group that was not vaccinated with the vaccine but was vaccinated with 17AD008 CIAV, and Figure 6D is a negative control group.
[0027]
[0028] Hereinafter, the present invention will be described in detail.
[0029] The present invention provides an attenuated strain SHK17 of chicken infectious anemia virus (Accession No.: KCTC14732BP).
[0030] The attenuated strain of chicken infectious anemia virus deposited under the accession number KCTC14732BP according to the present invention was obtained by subculturing a specific chicken infectious anemia virus (CIAV) isolated in Korea, and was deposited with the Biological Resource Center of the Korea Research Institute of Bioscience and Biotechnology on October 18, 2021 under the name Chicken infectious anaemis virus (CIAV) and assigned the accession number KCTC14732BP.
[0031] The SHK17 attenuated strain deposited under accession number KCTC14732BP according to the present invention can be obtained by serially subculturing domestic CIAV in host cells 50 to 200 times. Preferably, it can be obtained by serially subculturing 80 to 120 times, and more preferably, it can be obtained by serially subculturing 100 times.
[0032] According to one embodiment of the present invention, the SHK17 attenuated strain deposited under the accession number KCTC14732BP obtained by 100 consecutive subcultures has 1 × 107 TCID 50 / ml or higher virus titer.
[0033] In the present invention, any host cell that can be infected with CIAV and amplify CIAV can be used without limitation. Examples include, but are not limited to, MDCC-MSB1 (Chicken Lymphoblast cell line), Vero (African green monkey kidney cell line), or BHK-21 (Baby hamster kidney cell). In one embodiment of the present invention, MDCC-MSB1 (Chicken Lymphoblast cell line) was used as the host cell.
[0034] In addition, the SHK17 attenuated strain deposited under the above accession number KCTC14732BP is characterized by including a VP1 gene consisting of a base sequence represented by sequence number 3.
[0035] The above CIAV is divided into types I, IIa, IIb, IIIa, and IIIb according to the genotype of the full-length genome. As a result of performing a phylogenetic analysis based on the base sequence of the full-length genome of the CIAV in the examples of the present invention, it was confirmed that 17AD008, the parent virus of the SHK17 attenuated strain of the present invention, belongs to group IIIb. In addition, in the case of 17AD008 belonging to group IIIb, it was confirmed that lysine (K) and glutamic acid (E) were present in the amino acid sequences 139 and 144. In addition, glutamine (Q) was analyzed in the 394 sequence. This is known to cause high pathogenicity in host cells, and thus, it was determined that 17AD008 is highly pathogenic and exhibits a high proliferation rate.
[0036] Meanwhile, the VP1 gene (represented by SEQ ID NO: 3) included in the SHK17 attenuated strain according to the present invention showed differences in the 84th and 422nd base sequences from the VP1 gene (represented by SEQ ID NO: 1) included in 17A0008. More specifically, the 84th base of the VP1 gene (represented by SEQ ID NO: 1) included in 17A0008 was A, whereas the 84th base of the VP1 gene (represented by SEQ ID NO: 3) included in the SHK17 attenuated strain according to the present invention was G. In addition, the 422nd base of the VP1 gene (represented by SEQ ID NO: 1) included in 17A0008 was A, whereas the 422nd base of the VP1 gene (represented by SEQ ID NO: 3) included in the SHK17 attenuated strain according to the present invention was T. Therefore, it was confirmed that the SHK17 attenuated strain according to the present invention contains a VP1 gene that is clearly different from the parent virus 17AD008 through 100 subcultures.
[0037] Furthermore, according to one embodiment of the present invention, it was confirmed that the attenuated strain SHK17 of the present invention, which includes a VP1 gene consisting of a base sequence represented by the above SEQ ID NO: 3, exhibits significantly lower pathogenicity than 17AD008, which includes a VP1 gene consisting of a similar base sequence, and 17AD008-P45, which is obtained by subculturing the same 45 times. In particular, it was confirmed that the attenuated strain SHK17 deposited under the accession number KCTC14732BP exhibits a higher antibody titer and a longer retention period than commercial vaccines, confirming that it is significantly superior in preventing chicken infectious anemia.
[0038] Accordingly, the present invention provides a vaccine composition for preventing chicken infectious anemia, which includes an attenuated strain of chicken infectious anemia virus, SHK17 (Accession No.: KCTC14732BP).
[0039] In the present invention, the vaccine refers to a pharmaceutical product that provides animals with acquired immunity against a specific disease or pathogen. Vaccines typically have a structure similar to the antigen recognition site of a pathogen, but unlike the pathogen, they are non-pathogenic.
[0040] In the present invention, the vaccine is preferably a live or killed vaccine. It will be apparent to those skilled in the art that the present invention is not limited by the form of the vaccine, as long as it can induce the same or similar immune response. More preferably, the vaccine may be a live vaccine.
[0041] In the present invention, the above-mentioned "live vaccine (attenuated vaccine)" refers to a vaccine that is injected into an individual to which immunity is to be induced in a purified state, without killing the pathogen, thereby preventing the disease from occurring. In addition, the above-mentioned "killed vaccine (inactivated vaccine)" refers to a vaccine that is injected into an individual to which immunity is to be induced in a state in which a cultured pathogen is killed but the characteristics of the pathogen itself are maintained, thereby preventing the disease from occurring.
[0042] In addition, the vaccine composition of the present invention may additionally include an adjuvant (immunogenic agent, immune enhancing agent).
[0043] In the present invention, an adjuvant refers to a compound or mixture that enhances an immune response and / or promotes absorption after vaccination, and includes any absorption-promoting agent. Acceptable adjuvants include, but are not limited to, Freund's complete adjuvant, Freund's incomplete adjuvant, saponins, mineral gels such as aluminum hydroxide, surfactants such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, chiholmpet hemocyanin, dinitrophenol, and the like.
[0044] The vaccine composition for preventing chicken infectious anemia of the present invention may further comprise, in addition to the attenuated SHK17 strain, a pharmaceutically or veterinarily acceptable carrier or diluent. The term "pharmaceutically or veterinarily acceptable" refers to a composition that is physiologically acceptable and does not typically cause allergic reactions such as gastrointestinal upset or dizziness or similar reactions when administered to animals. Suitable carriers for vaccines are known to those skilled in the art and include, but are not limited to, proteins, sugars, etc. The carrier may be an aqueous or non-aqueous solution, suspension, or emulsion. Examples of non-aqueous carriers include propylene glycol, polyethylene glycol, edible oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcohol / aqueous solutions, emulsions, or suspensions, including saline and buffered media. Parenteral carriers include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.
[0045] Intravenous carriers include electrolyte replenishers, fluids, and nutritional supplements, such as those based on Ringer's dextrose. Preservatives and other additives may include, for example, antimicrobial agents, antioxidants, chelating agents, and inert gases. Preferred preservatives include formalin, thimerosal, neomycin, polymyxin B, and amphotericin B.
[0046] Additionally, the vaccine composition of the present invention can be formulated using methods known in the art to provide rapid, sustained, or delayed release of the active ingredient after administration to a mammal. The formulation can be in the form of powder, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injectable solutions, sterile powders, etc. The vaccine composition of the present invention can be administered via the intramuscular, subcutaneous, transdermal, intravenous, intranasal, intraperitoneal, or oral routes, and is preferably administered via the intramuscular or subcutaneous route. The dosage of the vaccine can be appropriately selected depending on various factors such as the route of administration, the age, sex, weight, and severity of the animal.
[0047] Additionally, the vaccine composition of the present invention can be prepared using standard methods known in the art. For example, the organism can be grown in a culture medium, such as complete medium, and the growth of the organism can be monitored using standard techniques, such as measuring color change units (CCU), and harvested when a sufficiently high titer is achieved. The stock can be further concentrated or lyophilized using conventional methods before being incorporated into a vaccine for formulation.
[0048] The present invention also provides a method for preventing infection with avian infectious anemia virus, comprising the step of administering a vaccine composition according to the present invention to poultry.
[0049] In the present invention, prevention of infection with the chicken infectious anemia virus is achieved through vaccination by administering a vaccine composition to poultry, and the “vaccination” means administering a pathogen with its pathogenicity removed or purified to an individual for whom immunity (i.e., antibody production) is to be induced in order to prevent an infectious disease.
[0050] The poultry described above may include, without limitation, individuals susceptible to infection with avian infectious anemia, and the method for vaccinating against such infection may be used in conjunction with other treatment or prevention methods known in the art. More preferably, the poultry may be chickens, and the chickens may include broilers, layers, breeders, etc. The term "vaccination" as used herein refers to providing a predetermined composition of the present invention to an individual by any suitable method.
[0051] The vaccination method of the present invention aims to prevent or improve the occurrence of an infectious disease that can be caused by the avian infectious anemia virus in poultry, preferably chickens.
[0052] The contents of the present invention described above are equally applicable to each other as long as they are not mutually contradictory, and it is also included in the scope of the present invention for a person skilled in the art to make appropriate changes and implement the present invention.
[0053]
[0054] Hereinafter, the present invention will be described in detail through examples, but the scope of the present invention is not limited to the following examples.
[0055]
[0056] Example 1. Molecular biological characteristics of CIAV (Chicken Infectious Anemia Virus)
[0057] Thymus or liver samples from chickens that showed clinical symptoms such as thymic atrophy, bone marrow discoloration, and petechial hemorrhages in the pectoralis or femoral muscles, or were confirmed to be infected with CIAV through antigen testing, were inoculated into MD lymphoma (Marek's disease lymphoma) cells (MDCC-MSB1) to culture and isolate CIAV. A total of 28 samples were obtained through this, and the numbers of each sample are as follows: 08AQ017A, 09AD301, 09AD354, 09AD367, 09AQ174, 09AQ183, 10AQ095, 10AQ135, 12AQ041, 16AD092, 17AD007, 17AD008, 18AD027, 18AD038, 18AD062, 18R001, 18R014B, 18R058B, 18R059, 18R072, 18R080, 18R083, 19AD011, 19AD028, 19AD069, 19AQ001, 19AQ023, 19AQ026.
[0058] The culture medium was then collected and DNA was extracted using the QIAamp DNA Mini kit (Qiagen, Germany) according to the manufacturer's instructions. Furthermore, the CIAV full-length genomes of the 28 strains were analyzed using the CIAV-specific primers shown in Table 1 below, and the results are shown in Table 2 below.
[0059] [Table 1]
[0060]
[0061] [Table 2]
[0062]
[0063] In addition, using the above-described genome sequence, phylogenetic analysis (Neighbor-Joining (NJ), Kimura 2-parameter model, bootstrapping 1000 replications) was performed with the MEGA-X (version 10.1.5.) program. As a result, as shown in Fig. 1, 28 CIAV strains isolated in Korea were classified into genotypes IIa (2 strains), IIb (9 strains), IIIa (8 strains), and IIIb (9 strains), excluding genotype I (each indicated by a red box). In Fig. 1, blue shapes indicate Cux-1, Cuxhaven-1, P4, and Del-Ros, which are commercially available vaccines and all belong to type IIIb. Domestic isolates showed 98.3-99.0% homology with CIAV isolated in Japan, China, Taiwan, and the United States, and the homology among domestic isolates was 96-98%. In addition, the major amino acid sequences of the VP1 protein related to the pathogenicity of CIAV were compared and shown in Fig. 2. In particular, amino acid sequences 139 and 144 were analyzed as glutamine (Q) in 20 genomes, which is known to indicate a low proliferation rate of the virus, and lysine (K) and glutamic acid (E) in type IIIb, which indicate a high proliferation rate in host cells. In addition, for sequence 394, all 28 strains were analyzed as glutamine, which is known to cause high pathogenicity in host cells. Based on this, 17AD008 was determined to be highly pathogenic and have a high proliferation rate. In fact, when each isolate was infected with MDCC-MSB1 cells, only the 17AD008 virus among the 28 strains showed a high titer of 1 X 107 TCID50 / ml or more after serial passage culture more than 40 times.
[0064]
[0065] Example 2. Confirmation of pathogenicity of CIAV 17AD008 isolate
[0066] To investigate its potential as a live vaccine, the 17AD008 virus was isolated and cultured in MDCC-MSB1 cells, and then serially passaged 45 and 100 times in MDCC-MSB1 cells, respectively. The isolate that was passaged 45 times was designated 17AD008-P45, and the isolate that was passaged 100 times was designated SHK17.
[0067] In addition, the VP1 gene sequences of the 17AD008 virus, 17AD008-P45, and SHK17 were confirmed. The VP1 gene sequence of the 17AD008 virus is as follows: ATGGCAAGACGAGCTCGCAGACCGAGAGGCCGATTTTACGCCTTCAGAAGAGGACGGTGGCACCACCTCAAGCGACTTCGACGATGGGAGCACCCGCATCAGAGATAGACACTAATTTCTTTACGCTTTACGTAGCGCAAGGCACAAATAAGTCGCAGCAGTACAAGTTCGGCACAGCTACATACGCGCTAAAGGAGCCGGTAATGAAGAGCGATTCATGGGCAGTGGTACGCGTCCAGTCGGTGTGGCAACTGGGTAACAGGCAAAGGCCATACCCATGGGACGTCAACTGGGCCAACAGCACCATGTACTGGGGGTCGCAGCCCTGA (SEQ ID NO: 1).
[0068] The genetic sequence of 17AD008-P45 is as follows:
[0069] ATGGCAAGACGAGCTCGCAGACCGAGAGGCCGATTTTACGCCTTCAGAAGAGGACGGTGGCACCACCTCAAGCGACTTCGACG(A / G)TGGGAGCACCCGCATCAGAGATAGACACTAATTTCTTTACGCTTTACGTAGCGCAAGGCACAAATAAGTCGCAGCAGT ACAAGTTCGGCACAGCTACATACGCGCTAAAGGAGCCGGTAATGAAGAGCGATTCATGGGCAGTGGTACGCGTCCAGTCGGTGTGGCAACTGGGTAACAGGCAAAGGCCATACCCATGGGACGTCAACTGGGCCAACAGCACCATGGACTGGGGGTCGCAGCCCTGA (SEQ ID NO: 2).
[0070] Additionally, the VP1 gene sequence of SHK17 is as follows: ATGGCAAGACGAGCTCGCAGACCGAGAGGCCGATTTTACGCCTTCAGAAGAGGACGGTGGCACCACCTCAAGCGACTTCGACGGTGGGAGCACCCGCATCAGAGATAGACACTAATTTCTTTACGCTTTACGTAGCGCAAGGCACAAATAAGTCGCAGCAGTAC AAGTTTCGGCACAGCTACATACGCGCTAAAGGAGCCGGTAATGAAGAGCGATTCATGGGCAGTGGTACGCGTCCAGTCGGTGTGGCAACTGGGTAACAGGCAAAGGCCATACCCATGGGACGTCAACTGGGCCAACAGCACCATGGACTGGGGGTCGCAGCCCTGA (SEQ ID NO: 3).
[0071] In addition, the above SHK17, 17AD008-P45 and commercially available live vaccine P4 (Nobilis® CAV P4, MSD Animal Health) were inoculated into the thigh of 1-day-old SPF chicks using the method shown in Table 3 below.
[0072] [Table 3]
[0073]
[0074] As a result, as shown in Fig. 3, thymic atrophy was observed in all treatment groups except control group G at 14 days after inoculation, and in particular, color changes due to fat deposition in the bone marrow were observed in group F, and death occurred after 17 days. Based on these macroscopic lesion results, the pathogenicity was confirmed by measuring the packed cell volume (PCV) to investigate whether anemia occurred due to infection with the chicken infectious anemia virus. As a result, as shown in Fig. 4, anemia (anemia standard ≤ 27%) occurred at 14 days in all groups except groups A and B. In particular, more severe anemia was induced in groups E and F, which were inoculated with high-titer viruses, than in groups C and D, which were inoculated with low-titer viruses, respectively, with the same virus.
[0075] Through this, it was confirmed that the vaccine candidate SHK17 according to the present invention had significantly weakened pathogenicity through 100 consecutive subcultures of 17AD008.
[0076] Furthermore, a comparison of ELISA antibody titers at 21 days post-vaccination revealed that group A, which received the attenuated virus according to this study, showed a significantly higher positivity rate, including higher antibody titers, than group B, which received the existing commercial vaccine. This confirmed that antibodies formed by SHK17 infection persisted longer than antibodies formed by the commercially available vaccine P4.
[0077] Therefore, it was confirmed that the vaccine candidate SHK17 according to the present invention showed superior efficacy than existing commercially available vaccines.
[0078]
[0079] Example 3. Confirmation of immunogenicity and protective capacity of CIAV 17AD008 isolate
[0080] Six-week-old SPF chickens were inoculated into the thigh with SHK17 (group A) and P4 commercial vaccine strain (group B) at 103.0 TCID50 / 0.2 ml each, and challenged with 17AD008 CIAV at 106.5 TCID50 / 0.2 ml in the thigh two weeks later. The positive control group (group C) was challenged with the same virus in the same manner, and the negative control group (group D) was challenged with PBS in the thigh. PCV was measured 14 days after challenge vaccination, and as shown in Figure 5, the PCV values of all groups at 10 weeks were normal, above 30%.
[0081] In addition, as shown in Figure 6, the results of comparing ELISA antibody titers before and after challenge vaccination by group showed that group A showed superior antibody formation ability than group B after challenge vaccination. Therefore, as with the previous results, it was confirmed that the vaccine candidate SHK17 of the present invention showed superior efficacy compared to existing commercially available vaccines.
[0082] The inventors of the present invention deposited the vaccine candidate SHK17 under the name of Chicken infectious anaemis virus (CIAV) at the Biological Resource Center of the Korea Research Institute of Bioscience and Biotechnology on October 18, 2021, and were assigned the deposit number KCTC14732BP.
[0083]
[0084] In summary, the live attenuated CIAV (Chicken Infectious Anemia Virus) vaccine strain SHK17 according to the present invention was obtained through 100 serial passages of the parent virus, and exhibited significantly lower pathogenicity than the parent virus and the virus obtained by serially passaged it 45 times, and exhibited higher antibody titers and a longer retention period than commercially available vaccines, and thus can be usefully utilized as a vaccine composition for preventing CIAV.
[0085]
[0086] [Accession number]
[0087] Name of depositor: Biological Resource Center, Korea Research Institute of Bioscience and Biotechnology
[0088] Accession number: KCTC14732BP
[0089] Date of acceptance: October 18, 2021
[0090]
[0091] [Correction pursuant to Rule 91, June 4, 2024]
Claims
1. Attenuated strain SHK17 of chicken infectious anemia virus (Accession number: KCTC14732BP).
2. In paragraph 1, The above SHK17 is an attenuated strain of chicken infectious anemia virus, characterized in that it comprises a VP1 gene consisting of a base sequence represented by sequence number 3 (Accession number: KCTC14732BP).
3. In paragraph 1, The above SHK17 is an attenuated strain of chicken infectious anemia virus, SHK17 (accession number: KCTC14732BP), characterized in that it is obtained through 80 to 120 passages of the parent virus.
4. In paragraph 1, The above SHK17 is an attenuated strain of chicken infectious anemia virus, characterized in that it belongs to group IIIb (Accession number: KCTC14732BP).
5. A vaccine composition for preventing chicken infectious anemia comprising an attenuated strain of chicken infectious anemia virus SHK17 (Accession number: KCTC14732BP).
6. In paragraph 5, A vaccine composition for preventing infectious anemia in chickens, characterized in that the vaccine is a live vaccine or an inactivated vaccine.
7. In paragraph 5, A vaccine composition for preventing infectious anemia in chickens, wherein the vaccine composition further comprises an adjuvant.
8. A method for preventing infection with avian infectious anemia virus, comprising the step of administering a vaccine composition according to Article 5 to poultry.
9. In paragraph 8, A method for preventing infection with avian infectious anemia virus, characterized in that the poultry is chicken.
10. In paragraph 8, A method for preventing infection with chicken infectious anemia virus, characterized in that the vaccine composition is administered by one or more methods selected from the group consisting of intramuscular, subcutaneous, transdermal, intravenous, intranasal, intraperitoneal, and oral.
Citation Information
Patent Citations
Integrated innovative startup platform system
KR1020240033578A
Chicken infectious anemia virus vaccine
WO1996001116A1
